Nicholls D P, O'Connor P C, Harron D W, Leahey W J, Shanks R G
Br J Clin Pharmacol. 1984 Jun;17(6):719-28. doi: 10.1111/j.1365-2125.1984.tb02409.x.
The effect of equihypotensive single oral doses of indoramin (mean dose 67 mg), phenoxybenzamine (mean dose 50 mg), hydralazine (mean dose 133 mg) and placebo on arterial pressure and heart rate in the supine and standing position was studied in six normal volunteers. Observations were made before and at 2 and 4 h after drug administration. Plasma noradrenaline (NA) was measured at each time interval in the supine position, and after 4 min of standing. Plasma renin activity (PRA) was measured at each time interval after 30 min in the standing position. The three active drugs reduced systolic arterial pressure in the standing position to a similar extent (indoramin, -24 mm Hg; phenoxybenzamine, -23.4 mm Hg; hydralazine, -30.4 mm Hg). The maximum effect of indoramin and phenoxybenzamine was observed at 4 h, and of hydralazine at 2 h after drug administration. The reductions of arterial pressure in the standing position were accompanied by increases in heart rate, plasma NA and PRA. Small increases were observed after indoramin (heart rate, + 9.2 beats min-1; plasma NA, + 126 pg/ml; PRA, + 0.33 ng angiotensin 1 ml-1 h-1), greater increases after phenoxybenzamine (heart rate, + 20; plasma NA, + 210; PRA, + 0.47), and the greatest increases after hydralazine (heart rate, + 26; plasma NA, + 250; PRA, + 1.16). In the supine position, indoramin and phenoxybenzamine produced no effect on arterial pressure, heart rate or plasma NA. Hydralazine produced small reductions in diastolic pressure, which were accompanied by an increase in heart rate of 25.5 beats min-1 (P less than 0.01 when compared to placebo) and in plasma NA of 223 pg ml-1 (P less than 0.05). Plasma NA, PRA and heart rate increased together and may be regarded as three interdependent indices of sympathetic activity. Indoramin reduced the degree of increase of plasma NA, PRA and heart rate per unit fall in pressure, when compared to phenoxybenzamine and hydralazine. The effect of phenoxybenzamine and hydralazine on the degree of increase was similar. The results are consistent with the hypothesis that indoramin produces selective postsynaptic alpha 1-adrenoceptor blockade in man, and therefore produces relatively less tachycardia and NA increase than does a non-selective alpha-adrenoceptor antagonist (phenoxybenzamine) or an arteriolar vasodilator (hydralazine).
在6名正常志愿者中研究了等降压单剂量口服吲哚拉明(平均剂量67毫克)、酚苄明(平均剂量50毫克)、肼屈嗪(平均剂量133毫克)和安慰剂对仰卧位和站立位动脉压及心率的影响。在给药前以及给药后2小时和4小时进行观察。在仰卧位的每个时间间隔以及站立4分钟后测量血浆去甲肾上腺素(NA)。在站立位30分钟后的每个时间间隔测量血浆肾素活性(PRA)。三种活性药物使站立位收缩压降低的程度相似(吲哚拉明,-24毫米汞柱;酚苄明,-23.4毫米汞柱;肼屈嗪,-30.4毫米汞柱)。吲哚拉明和酚苄明的最大效应在给药后4小时观察到,肼屈嗪的最大效应在给药后2小时观察到。站立位动脉压降低伴随着心率、血浆NA和PRA升高。吲哚拉明给药后观察到小幅升高(心率,+9.2次/分钟;血浆NA,+126皮克/毫升;PRA,+0.33纳克血管紧张素1毫升-1小时-1),酚苄明给药后升高幅度更大(心率,+20;血浆NA,+210;PRA,+0.47),肼屈嗪给药后升高幅度最大(心率,+26;血浆NA,+250;PRA,+1.16)。在仰卧位,吲哚拉明和酚苄明对动脉压、心率或血浆NA无影响。肼屈嗪使舒张压小幅降低,同时心率增加25.5次/分钟(与安慰剂相比P<0.01),血浆NA增加223皮克/毫升(P<0.05)。血浆NA、PRA和心率共同升高,可被视为交感神经活动的三个相互依存指标。与酚苄明和肼屈嗪相比,吲哚拉明降低了每单位压力下降时血浆NA、PRA和心率的升高程度。酚苄明和肼屈嗪对升高程度的影响相似。这些结果与以下假设一致:吲哚拉明在人体中产生选择性突触后α1-肾上腺素能受体阻滞,因此与非选择性α-肾上腺素能受体拮抗剂(酚苄明)或小动脉血管扩张剂(肼屈嗪)相比,产生的心动过速和NA升高相对较少。